Qinghai Spring(SH:600381)2023-04-28 16:00Financial Performance - The company's consolidated net profit attributable to shareholders for 2022 was -287,548,928.51 RMB, while the parent company's net profit was -215,884,196.82 RMB[4]. - Total revenue for 2022 reached 160,178,078.61 RMB, representing a 25.37% increase compared to 2021[22]. - The net cash flow from operating activities was -31,821,162.74 RMB, showing an improvement from -63,933,807.38 RMB in the previous year[22]. - The total assets at the end of 2022 were 1,559,229,152.99 RMB, a decrease of 15.63% from the previous year[22]. - The net assets attributable to shareholders decreased by 15.80% to 1,532,931,572.40 RMB compared to the end of 2021[22]. - The net loss attributable to shareholders was 287.55 million RMB, with a non-GAAP net loss of 262.52 million RMB, indicating an increase in losses compared to the previous year[33]. - The company reported a total operating loss of 129.74 million RMB, accounting for 45.12% of the total losses, due to increased marketing expenses of 123.24 million RMB, which grew by 121.34%[37]. - The total comprehensive loss for 2022 was ¥287,550,325.75, compared to a loss of ¥248,610,919.96 in 2021, highlighting ongoing financial challenges[192]. Revenue Breakdown - The company reported a significant increase in revenue from core business activities, with a total of 155,045,737.02 RMB, up 34.52% from 2021[22]. - The company's operating revenue for 2022 was 160.18 million RMB, an increase of 25.37% year-on-year[33]. - The revenue from core business, after excluding unrelated income, was 155.05 million RMB, up 34.52% year-on-year[33]. - The health product segment, primarily focused on the sales of Cordyceps and traditional Chinese medicine, generated revenue of 4.17 million RMB, a year-on-year increase of 35.66%[37]. - The sales revenue from the liquor fast-moving consumer goods segment reached 93.64 million RMB, representing a year-on-year growth of 268.75%[36]. - The sales revenue from traditional Chinese medicine products, specifically the "Lifelong Tablets," grew by 35.66% to 41.69 million yuan[46]. - The sales of Cordyceps sinensis raw grass decreased by 66.63%, generating revenue of 19.71 million yuan[46]. Expenses and Costs - The company's marketing expenses surged by 121.34% to 123.24 million yuan, primarily due to increased market promotion costs in the fast-moving consumer goods sector[48]. - The company recognized asset impairment losses of 92.84 million RMB and credit impairment losses of 27.18 million RMB during the reporting period[33]. - Total operating costs for 2022 were ¥289,917,807.91, up 23.8% from ¥234,086,137.04 in 2021[191]. Research and Development - The research and development expenses increased by 19.29% to 11.38 million yuan, reflecting the company's commitment to innovation[48]. - The number of R&D personnel is 12, accounting for 6.9% of the total workforce[62]. - Research and development expenses increased to ¥11,377,981.32 in 2022, up from ¥9,538,458.61 in 2021, indicating a focus on innovation[194]. Governance and Compliance - The company has established a comprehensive internal governance system, ensuring compliance with laws and regulations while safeguarding shareholder interests and sustainable development[102]. - The board of directors has set up specialized committees to enhance governance and ensure effective decision-making processes[103]. - The company maintains independence from its controlling shareholders in business, financial, and operational aspects, ensuring fair treatment in related transactions[103]. - The company has established a series of regulations related to information management and disclosure, including the "Board Secretary Work System" and "Information Disclosure Management Measures," ensuring compliance with the Shanghai Stock Exchange's requirements[104]. - During the reporting period, the company did not experience any violations of information disclosure or insider trading activities[104]. Market and Strategic Initiatives - The company focused on the fast-moving consumer goods and health sectors, emphasizing innovation and product upgrades[33]. - The company plans to launch upgraded products "Sauce Aroma PLUS" and "Strong Aroma PLUS" in June 2023, which will feature at least 24 additional aroma notes and enhanced taste dimensions[35]. - The company has established joint ventures with local partners to expand sales channels, holding 51% equity in each of the new companies[36]. - The company aims to leverage the recovery of domestic consumption and pursue health-oriented product offerings, focusing on innovation in liquor quality and taste[93]. Shareholder Information - The total number of common shareholders as of the end of the reporting period is 68,470, an increase from 56,195 at the end of the previous month[156]. - The largest shareholder, Tibet Rong'en Technology Co., Ltd., holds 33.07% of the shares, amounting to 194,115,194 shares, with 151,110,000 shares pledged[158]. - The second-largest shareholder, Xiao Rong, holds 9.67% of the shares, totaling 56,762,789 shares, with 40,942,959 shares pledged[159]. Environmental and Social Responsibility - The company invested 468,000 RMB in environmental protection during the reporting period[136]. - The company is exploring solar power generation projects and plans to utilize idle factory roof resources for distributed photovoltaic power generation[138]. - The company has implemented measures to reduce carbon emissions, including using solar preheating systems and recovering boiler flue gas waste heat[138]. - The company actively participates in community public welfare activities and promotes a harmonious community[139]. - The company emphasizes product quality and environmental protection as part of its corporate social responsibility initiatives[139].